To read the full article sign up for free or sign in.

More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal

Jan. 23, 2025

A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.

BioWorld Science Deals and M&A Cancer Gastrointestinal Antibody-drug conjugate Asia-Pacific China U.S.

Today's news in brief

BioWorld

BioWorld briefs for Feb. 7, 2025.

European VCs optimistic for med-tech exit opportunities in 2025

BioWorld MedTech

To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for February 7, 2025

3D illustration of acute myeloid leukemia cells

Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML

BioWorld

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...

Radiopharma Advancell raises $112M in series C for alpha therapies

BioWorld

Aussie radiopharma company Advancell Co. Ltd. closed an oversubscribed $112 million series C round that will accelerate clinical development of its pipeline of...